NASDAQ:IRTC - Irhythm Technologies Stock Price, Forecast & News

Irhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."

Irhythm Technologies Inc (NASDAQ:IRTC) announced its earnings results on Thursday, February, 27th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.12. The firm earned $59.10 million during the quarter, compared to analyst estimates of $58.42 million. Irhythm Technologies had a negative return on equity of 67.44% and a negative net margin of 26.45%. The business's quarterly revenue was up 41.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.61) earnings per share. View Irhythm Technologies' Earnings History.

Irhythm Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Irhythm Technologies.

Irhythm Technologies issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $280-290 million, compared to the consensus revenue estimate of $283.61 million.

7 Wall Street analysts have issued 12 month price targets for Irhythm Technologies' shares. Their forecasts range from $90.00 to $125.00. On average, they expect Irhythm Technologies' stock price to reach $106.80 in the next year. This suggests a possible upside of 28.4% from the stock's current price. View Analyst Price Targets for Irhythm Technologies.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Irhythm Technologies in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Irhythm Technologies.

Press coverage about IRTC stock has been trending very negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Irhythm Technologies earned a media sentiment score of -3.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Irhythm Technologies.

Some companies that are related to Irhythm Technologies include Novocure (NVCR), ABIOMED (ABMD), Hill-Rom (HRC), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Integra Lifesciences (IART), Tandem Diabetes Care (TNDM), Nevro (NVRO), ICU Medical (ICUI), NuVasive (NUVA), Cantel Medical (CMD), Glaukos (GKOS), Merit Medical Systems (MMSI) and Inspire Medical Systems (INSP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Irhythm Technologies investors own include Twilio (TWLO), Tandem Diabetes Care (TNDM), Alibaba Group (BABA), Canopy Growth (CGC), NVIDIA (NVDA), Paypal (PYPL), Paycom Software (PAYC), DexCom (DXCM), Splunk (SPLK) and Square (SQ).

(IRTC) raised $76 million in an IPO on Thursday, October 20th 2016. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Irhythm Technologies' stock is owned by many different of retail and institutional investors. Top institutional investors include Capital Research Global Investors (7.91%), William Blair Investment Management LLC (4.64%), Alliancebernstein L.P. (3.38%), Franklin Resources Inc. (2.56%), State Street Corp (2.53%) and Victory Capital Management Inc. (1.86%). Company insiders that own Irhythm Technologies stock include Bruce G Bodaken, David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Merz Cathleen Noel Bairey, Raymond W Scott and Vijay K Lathi. View Institutional Ownership Trends for Irhythm Technologies.

IRTC stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Franklin Resources Inc., Lord Abbett & CO. LLC, Sectoral Asset Management Inc, Goldman Sachs Group Inc., Fiera Capital Corp, Man Group plc and First Trust Advisors LP. Company insiders that have sold Irhythm Technologies company stock in the last year include David A Vort, Kevin M King, Matthew C Garrett and Merz Cathleen Noel Bairey. View Insider Buying and Selling for Irhythm Technologies.

IRTC stock was bought by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Renaissance Technologies LLC, Capital Research Global Investors, Alliancebernstein L.P., Victory Capital Management Inc., State Street Corp, Victory Capital Management Inc. and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Irhythm Technologies.

Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IRTC stock can currently be purchased for approximately $83.17.

Irhythm Technologies has a market capitalization of $2.21 billion and generates $147.29 million in revenue each year. The company earns $-48,280,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Irhythm Technologies employs 748 workers across the globe.View Additional Information About Irhythm Technologies.

The official website for Irhythm Technologies is http://www.irhythmtech.com/.

Irhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]